Valeriana Species: In Vitro Culture and the Formation of Sesquiterpenes and Valepotriates

  • F. Gränicher
  • P. Christen
Part of the Biotechnology in Agriculture and Forestry book series (AGRICULTURE, volume 33)


The members of Valerianaceae have a long history of use as a sedative in Europe and Asia. Nardostachys chinensis Batalin and N. jatamansii DC have been used for centuries in China and India to cure various psychiatric disorders such as epilepsy and overexcitement (Rücker 1979; Houghton 1988). Besides these two species, some Valeriana species are extensively used nowadays as sedatives, e.g., V. wallichii DC in India, V. officinalis L. var angustifolia in Japan, and V. officinalis L. s.l. in Europe (Rücker 1979). This latter species was already known to the Greeks and Romans as diuretic, analgesic, and spasmolytic drug. Since the 18th century Western medicine has used V. officinalis for its sedative properties. The roots of this plant are included in the second edition of the European Pharmacopoeia (1985).


Hairy Root Cell Suspension Culture Valerenic Acid Nontransformed Plant Hydroxyvalerenic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Balduini W, Cattabeni F (1989) Displacement of [3H]-N6-cyclohexyladenosine binding to rat cortical membranes by an hydroalcoholic extract of Valeriana officinalis. Med Sci Res 17: 639–640Google Scholar
  2. Bäumer JJ, Becker H (1983) Growth inhibition of a Valeriana wallichii cell culture by branched-chain amino acids. Z Planzenphysiol 110: 107–112Google Scholar
  3. Becker H, Bäumer JJ (1983) Isolation and characterisation of cell lines of Valeriana wallichii resistant to trifluoroleucine. Z Planzenphysiol 112: 43–51Google Scholar
  4. Becker H, Chavadej S (1985) Valepotriate production of normal and colchicine-treated cell suspension cultures of Valeriana wallichii. J Nat Prod 48: 17–21PubMedCrossRefGoogle Scholar
  5. Becker H, Chavadej S (1988) Valepotriates: production by plant cell cultures. In: Bajaj YPS (ed) Biotechnology in agriculture and forestry, vol 4. Medicinal and aromatic plants I. Springer, Berlin Heidelberg New York, pp 294–309Google Scholar
  6. Becker H, Herold S (1983) RP-8 als Hilfsphase zur Akkumulation von Valepotriaten aus Zellsuspensionskulturen von Valeriana wallichii. Planta Med 49: 191–192PubMedCrossRefGoogle Scholar
  7. Becker H, Schrall R (1980) Valepotriates in tissue cultures of nine different Valerianaceae species in comparison to literature data of the intact plants. J Nat Prod 43: 721–723PubMedCrossRefGoogle Scholar
  8. Becker H, Schrall R, Hartmann W (1977) Anlage einer Calluskultur von Valeriana wallichii DC. und erste analytische Untersuchungen. Arch Pharm 310: 481–484CrossRefGoogle Scholar
  9. Becker H, Chavadej S, Thies PW, Finner E (1984) Die Struktur neuer Valepotriate aus Colchicinbehandelten Zellkulturen von Valeriana wallichii. Planta Med 50: 245–248PubMedCrossRefGoogle Scholar
  10. Bellesia F, Pagnoni UM, Pinetti A, Trave R (1983) Teucrein, a new iridolactol from Teucrium marum, and its biosynthetic relationship with dolichodial. J Chem Res Synop 328–329Google Scholar
  11. Chavadej S, Becker H (1984) Influence of colchicine treatment on chromosome number and growth rate of tissue cultures of Valeriana wallichii DC. Plant Cell Tissue Organ Cult 3: 265–272CrossRefGoogle Scholar
  12. Clare BG (1990) Agrobacterium in plant disease, biological disease control and plant genetic engineering. Sci Prog 74: 1–13PubMedGoogle Scholar
  13. European Pharmacopoeia (1985) 2nd edn. Maisonneuve (ed), Sainte-Ruffine, 453 ppGoogle Scholar
  14. Evans WC (1989) Trease and Evans’ pharmacognosy, 13th edn. Baillière Tindall, London, pp 525–528Google Scholar
  15. Fink C, Hölzl J, Rieger H, Krieglstein J (1984) Wirkungen von Valtrat auf das EEG des isoliert perfundierten Rattenhirns. Arzneim Forsch 34: 170–174Google Scholar
  16. Förster W, Becker H (1987) Effects of plant bioregulators on the production of iridoid derived terpenoids in Valeriana wallichii and Fedia cornucopiae cell suspension cultures. Z Naturforsch 42: 33–40Google Scholar
  17. Funk C, Brodelius P (1990) Influence of growth regulators and an elicitor on phenylpropanoid metabolism in suspension cultures of Vanilla planifolia. Phytochemistry 29: 845–848CrossRefGoogle Scholar
  18. Gamborg OL (1970) The effects of amino-acids and ammonium on the growth of plant cells in suspension culture. Plant Physiol 45: 372–375PubMedCrossRefGoogle Scholar
  19. Gränicher F, Christen P, Kapétanidis I (1992) High-yield production of valepotriates by hairy root cultures of Valeriana officinalis L. var sambucifolia Mikan. Plant Cell Rep 11: 339–342CrossRefGoogle Scholar
  20. Gränicher F, Christen P, Kamalaprija P, Burger U (1995) An iridoid diester from Valeriana officinalis var. sambucifolia hairy roots. Phytochemistry 38: 103–105CrossRefGoogle Scholar
  21. Gränicher F, Christen P, Vuagnat P (1994) Rapid HPLC quantification of valepotriates. Phytochem Anal. 5: 297–301CrossRefGoogle Scholar
  22. Handjieva NV, Zaikin VG (1978) DIA-Valtrate, a new valepotriate from Centranthus ruber (L.) DC. Planta Med 34: 203–206CrossRefGoogle Scholar
  23. Hänsel R, Schulz J (1982) Valerensäuren und Valerenal als Leitstoffe des offizinellen Baldrians. Dtsch Apoth Ztg 122: 215–219Google Scholar
  24. Hazelhoff B (1984) Phytochemical and pharmacological aspects of valerian compounds. PhD Thesis, Univ Groningen, The NetherlandsGoogle Scholar
  25. Hazelhoff B, Weert B, Denee R, Malingré ThM (1979) Isolation and analytical aspects of Valeriana compounds. Pharm Weekbl Sci Ed 114: 956–964CrossRefGoogle Scholar
  26. Hazelhoff B, Malingré ThM, Meijer DKF (1982) Antispasmodic effects of valeriana compounds: an in-vivo and in-vitro study on the guinea-pig ileum. Arch Int Pharmacodyn 257: 274–287PubMedGoogle Scholar
  27. Hegnauer R (1973) Chemotaxonomie der Pflanzen, vol 6. Birkhäuser, Basel, pp 638–657Google Scholar
  28. Hegnauer R (1990) Chemotaxonomie der Pflanzen, vol 9. Birkhäuser, Basel, pp 720–731Google Scholar
  29. Hendriks H, Bos R, Allersma DP, Malingré ThM, Koster ASJ (1981) Pharmacological screening of valerenal and some other components of essential oil of Valeriana officinalis. Planta Med 42: 62–68PubMedCrossRefGoogle Scholar
  30. Hendriks H, Bos R, Woerdenbag HJ, Koster ASJ (1985) Central nervous depressant activity of valerenic acid in the mouse. Planta Med 51: 28–31PubMedCrossRefGoogle Scholar
  31. Hölzl J, Fink C (1984) Untersuchungen zur Wirkung der Valepotriate auf die Spontanmobilität von Mäusen. Arzneim Forsch 34: 44–47Google Scholar
  32. Hooykaas PJJ, Klapwijk PM, Nuti MP, Schilperoort RA, Rörsch A (1977) Transfer of the Agrobacterium tumefaciens TI plasmid to avirulent Agrobacteria and to Rhizobium ex planta. J Gen Microbiol 98: 477–484CrossRefGoogle Scholar
  33. Houghton PJ (1988) The biological activity of valerian and related plants. J Ethnopharmacol 22: 121–142PubMedCrossRefGoogle Scholar
  34. Leathwood PD, Chauffard F (1985) Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med 51: 144–148CrossRefGoogle Scholar
  35. Leathwood PD, Chauffard F, Heck E, Munoz-Box R (1982) Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man. Pharmacol Biochem Behav 17: 65–71PubMedCrossRefGoogle Scholar
  36. Lee S-L, Cheng K-D, Scott AI (1981) Effects of bioregulators on indole alkaloid biosynthesis in Catharanthus roseus cell culture. Phytochemistry 20: 1841–1843CrossRefGoogle Scholar
  37. Lloyd G, McCown B (1980) Commercially-feasible micropropagation of mountain laurel Kalmia latifolia, by use of shoot-tip culture. Proc Int Plant Prop Soc 30: 421–427Google Scholar
  38. Mathur J (1992) Plantlet regeneration from suspension cultures of Valeriana wallichii DC. Plant Sci 81: 111–115CrossRefGoogle Scholar
  39. Mathur J, Ahuja PS, Mathur AK, Kukreja AK, Shah NC (1988) In vitro propagation of Valeriana wallichii. Planta Med 54: 82–83PubMedCrossRefGoogle Scholar
  40. Mathur J, Ahuja PS, Lal N, Mathur AK (1989) Propagation of Valeriana wallichii DC. using encapsulated apical and axial shoot buds. Plant Sci 60: 111–116CrossRefGoogle Scholar
  41. Mennini T, Bernasconi P, Bombardelli E, Morazzoni P (1993) In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 64: 291–300Google Scholar
  42. Murashige T, Skoog F (1962) A revised medium for rapid growth and bioassays with tobacco tissue cultures. Physiol Plant 15: 473–497CrossRefGoogle Scholar
  43. Petit A, David C, Dahl GA, Ellis JG, Guyon P (1983) Further extension of the opine concept: plasmids in Agrobacterium rhizogenes cooperate for opine degradation. Mol Gen Genet 190: 204–214CrossRefGoogle Scholar
  44. Pythoud F, Sinkar VP, Nester EW, Gordon MP (1987) Increased virulence of Agrobacterium rhizogenes conferred by the vir region of pTiBo542: application to genetic engineering of poplar. Biotechnology 5: 1323–1327CrossRefGoogle Scholar
  45. Riedel E, Hänsel R, Ehrke G (1982) Hemmung des γ-Aminobuttersäureabbaus durch Valerensäurederivate. Planta Med 46: 219–220PubMedCrossRefGoogle Scholar
  46. Ries SK, Wert V, Sweeley CC, Leavitt RA (1977) Triacontanol: a new naturally occurring plant growth regulator. Science 195: 1339–1341PubMedCrossRefGoogle Scholar
  47. Rücker G (1979) Über die Wirkstoffe der Valerianaceen. Pharm unserer Zeit 8: 78–86PubMedCrossRefGoogle Scholar
  48. Rücker G, Tautges J, Sieck A, Wenzl H, Graf E (1978) Untersuchungen zur Isolierung und pharmakodynamischen Aktivität des Sesquiterpenes Valeranon aus Nardostachys jatamansi DC. Arzneium Forsch 28: 7–13Google Scholar
  49. Santos MS, Ferriera F, Cunha AP, Carvalho AP, Ribeiro CF, Macedo T (1994) Synaptosomal GABA release as influenced by valerian root extract-involvement of GABA carrier. Arch Int Pharmacodyn Ther 327: 220–231PubMedGoogle Scholar
  50. Schrall R, Becker H (1980) Valepotriate in Callus- und Suspensionskulturen von verschiedenen Valerianaceen. Acta Hortic 96: 75–83Google Scholar
  51. Stahl E, Schild W (1969) Ein charakteristisches chromogenes Valepotriat ohne Dienstruktur in Valerianaceen. Tetrahedron Lett 13: 1053–1056CrossRefGoogle Scholar
  52. Stahl E, Schild W (1981) Drogen mit aequilibrierenden Inhaltsstoffen. In: Pharmazeutische Biologie Drogenanalyse II: Inhaltsstoffe und Isolierungen. Gustav Fischer, Stuttgart, pp 192–198Google Scholar
  53. Steinegger E (1953) Grundlagen und Ergebnisse der Heteroploidie-Züchtung bei Arzneipflanzen. Sci Pharm 21: 168–186Google Scholar
  54. Suga T, Hirata T, Shishibori T, Tange K (1974) The first proof of the biosynthesis of isoprenoid from amino acid in higher plant. The incorporation of L-leucine into linalool. Chem Lett 189–192Google Scholar
  55. Suga T, Hirata T, Tange K (1975a) Biosynthesis of isoprenoid from amino acid in higher plant. Incorporation of L-valine into linalool. Chem Lett 131–132Google Scholar
  56. Suga T, Hirata T, Tange K (1975b) Biosynthesis of isoprenoid from amino acid in higher plant. Incorporation of L-leucine and L-valine into geraniol and citronellol. Chem Lett 243–246Google Scholar
  57. Suga T, Tange K, Iccho K, Hirata T (1980) Biosynthesis of triterpenoids from amino acids in Pisum sativum. The distribution of the radioactivity in squalene biosynthesized from radioisotopically labelled L-leucine and L-valine. Phytochemistry 19: 67–70CrossRefGoogle Scholar
  58. Thies PW (1968) Die Konstitution der Valepotriate. Mitteilung über die Wirkstoffe des Baldrians. Tetrahedron 24: 313–347CrossRefGoogle Scholar
  59. Thies PW, Finner E, Rosskopf F (1973) Über die Wirkstoffe des Baldrians. 10: Die Konfiguration des Valtratum und anderer Valepotriate. Tetrahedron 29: 3213–3226CrossRefGoogle Scholar
  60. Thies PW, Finner E, David S (1981) Über die Wirkstoffe des Baldrians. 14: Die Konstitutive Zuordnung der Acyloxysubstituenten in Valepotriaten via C 13-NMR-Spektroskopie. Planta Med 41: 15–20PubMedCrossRefGoogle Scholar
  61. Tufik S, Fujita K, Seabra M, Lobo LL (1994) Effects of a prolonged administration of valepotriates in rats on the mothers and their offspring. J Ethnopharmacol 41: 39–44PubMedCrossRefGoogle Scholar
  62. Veith J, Schneider G, Lemmer B, Willems M (1986) Einfluss einiger Abbauprodukte von Valepotriaten auf die Mobilität Licht-Dunkel synchronisierter Mäuse. Planta Med 52: 179–183CrossRefGoogle Scholar
  63. Viola U, Fritz D (1991) In vitro-Vermehrung von Valeriana wallichii DC. in verschiedenen Medien. Gartenbauwissenschaft 56: 21–25Google Scholar
  64. Violon C, Van Cauwenbergh N, Vercruysse A (1983) Valepotriate content in different in vitro cultures of Valerianaceae and characterization of Valeriana officinalis L. callus during a growth period. Pharm Weekbl Sci Ed 5: 205–209CrossRefGoogle Scholar
  65. Violon C, Dekegel D, Vercruysse A (1984) Relation between valepotriate content and differentiation level in various tissues from Valerianeae. J Nat Prod 47: 934–940CrossRefGoogle Scholar
  66. Von Eickstedt K-W, Rahman S (1969) Psychopharmakologische Wirkungen von Valepotriaten. Arzneim Forsch 19: 316–319Google Scholar
  67. Wagner H, Jurcic K (1979) Uber die spasmolytische Wirkung des Baldrians. Planta Med 37: 84–95PubMedCrossRefGoogle Scholar
  68. Wagner H, Jurcic K, Schaette R (1980) Vergleichende Untersuchungen über die sedierende Wirkung von Baldrianextrakten, Valepotriaten und ihren Abbauprodukten. Planta Med 38: 358–365CrossRefGoogle Scholar
  69. White FF, Ghidossi G, Gordon MP, Nester EW (1982) Tumor induction by Agrobacterium rhizogenes involves the transfer of plasmid DNA to the plant genome. Proc Natl Acad Sci USA 79: 3193–3197PubMedCrossRefGoogle Scholar
  70. Wienschierz H-J (1978) Erfahrungen bei der Kultivierung von Valeriana wallichii D.C. in der Bundesrepublik Deutschland. Acta Hortic 73: 315–321Google Scholar
  71. Yokoyama H, Hsu WH, Hayman E, Poling SM (1984) Bioregulation of plant constituents. Recent Adv Phytochem 18: 231–250Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • F. Gränicher
  • P. Christen
    • 1
  1. 1.Department of PharmacognosyUniversity of Geneva, Sciences IIGeneva 4Switzerland

Personalised recommendations